Compounds > 9,10,13-trihydroxy-11-octadecenoic acid
Page last updated: 2024-12-10
9,10,13-trihydroxy-11-octadecenoic acid
Description
9,10,13-trihydroxy-11-octadecenoic acid: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
9,10,13-TriHOME : A TriHOME that is (11E)-octadec-11-enoic acid in which the three hydroxy substituents are located at positions 9, 10 and 13. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 5282965 |
| CHEBI ID | 34499 |
| SCHEMBL ID | 1134687 |
| MeSH ID | M0245171 |
Synonyms (18)
| Synonym |
|---|
| 9,10,13-trihome |
| (11e)-9,10,13-trihydroxyoctadec-11-enoic acid |
| 9,10,13-trihydroxyoctadec-11-enoic acid |
| 9,10,13-3ohc18a |
| 11-octadecenoic acid, 9,10,13-trihydroxy-, (e)- |
| (e)-9,10,13-trihydroxy-11-octadecenoic acid |
| 29907-57-1 |
| 9,10,13-trihydroxy-11-octadecenoic acid |
| (e)-9,10,13-trihydroxyoctadec-11-enoic acid |
| LMFA02000168 |
| 9,10,13-trihome(11) |
| 11-octadecenoic acid, 9,10,13-trihydroxy-, (11e)- |
| 185253-41-2 |
| SCHEMBL1134687 |
| CHEBI:34499 |
| (11e)-9,10,13-trihydroxyoctadecenoic acid |
| DTXSID90904326 |
| Q27116111 |
Roles (1)
| Role | Description |
|---|
| human blood serum metabolite | Any metabolite (endogenous or exogenous) found in human blood serum samples. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (4)
| Class | Description |
|---|
| TriHOME | A trihydroxyoctadecenoic acid metabolite of linoleic acid formed by formal hydroxylation across one of the double bonds of hydroperoxyoctadecadienoic acids (HPODEs). |
| monounsaturated fatty acid | Any fatty acid with one double or triple bond in the fatty acid chain and singly bonded carbon atoms in the rest of the chain. MUFAs have positive effects on the cardiovascular system, and in diabetes treatment. |
| long-chain fatty acid | A fatty acid with a chain length ranging from C13 to C22. |
| straight-chain fatty acid | Any fatty acid whose skeletal carbon atoms form an unbranched open chain. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (4)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 13.13
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 13.13 (24.57) | | Research Supply Index | 1.79 (2.92) | | Research Growth Index | 4.92 (4.65) | | Search Engine Demand Index | 0.00 (26.88) | | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |